Transforming medicine

Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

Interim Results for the Six Months ended 30 June 2019

Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession

Editorial on Positive Data for BARHEMSYS® Treatment of PONV Published in Anesthesia & Analgesia

Acacia Pharma Plans to Resubmit the BARHEMSYS® NDA in Q3 2019

Annual General Meeting Results and Statement

Acacia Pharma’s BARHEMSYS® Significantly Improves Post-operative Nausea & Vomiting (PONV) in Rescue Treatment of Ambulatory Patients

Notice of Annual General Meeting

Acacia Pharma Receives Complete Response Letter from FDA for BARHEMSYS®

Positive Phase 3 BARHEMSYS® Rescue Treatment Data to be Presented at the Annual Congress of Enhanced Recovery and Perioperative Medicine

Results for the year ended 31 December 2018

Editorial in Anesthesiology on Positive Data for BARHEMSYS™ PONV Rescue Treatment

Supportive Cardiac Safety Data for BARHEMSYS™

Positive Clinical Results for APD403 in CINV Published in Supportive Care in Cancer

New BARHEMSYS™ PDUFA date confirmed for 5 May 2019

Positive BARHEMSYS™ Rescue Treatment Data Published in Anesthesiology

Acacia Pharma Resubmits BARHEMSYS™ New Drug Application

Unaudited Results for the nine months to 30 September 2018

Further update on FDA regulatory review of BARHEMSYS™ 

Update on FDA regulatory review of BARHEMSYS™